Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Exxon Mobil Corporation (XOM) Price & Performance

DexCom, Inc.Trade
Exxon Mobil CorporationTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Exxon Mobil Corporation — how do they compare? DexCom, Inc. trades at $89.44 (market cap $33.79B), while Exxon Mobil Corporation trades at $159.12 (market cap $657.08B). The key difference: Exxon Mobil Corporation is far larger — about 19.4× DexCom, Inc.'s market cap, and Exxon Mobil Corporation pays a 2.58% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.

DXCMXOM
Market Cap
$33.79B$657.08B
Sector
HealthEnergy
52-Week High
$89.53$171.52
52-Week Low
$54.84$106.13
Enterprise Value
$33.24B$688.86B
Dividend Yield
2.58%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.

The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.

Exxon Mobil Corporation

ExxonMobil (XOM) trades at $159.79, up 4.48% today, showing strong momentum near its consensus price target of $163.71. The stock maintains a bullish technical outlook with support at $156 and resistance at $162. Recent earnings show mixed results with Q2 2026 missing expectations, but profitability remains solid with a 9.07% net margin and 12.55% ROE. The company benefits from high oil prices and strategic Permian Basin operations, though revenue has declined from $398.7B in 2022 to $323.9B in 2025.

XOM presents a balanced investment case with analyst consensus leaning toward Hold (51.85%). Upside potential exists from oil price strength and operational efficiency, but risks include volatile energy markets and declining revenue trends. The stock's current valuation at 20.57x P/E appears reasonable given stable dividends and strong cash flow generation. Institutional sentiment remains cautiously optimistic with price targets suggesting modest upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About Exxon Mobil Corporation

Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.

Read more on XOM